These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Subscribe To Our Newsletter & Stay Updated
